Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial

Background Treatment of moderate-to-severe plaque psoriasis with biologics, such as guselkumab, has demonstrated greater efficacy over traditional non-biologic treatments. However, given patient diversity, greater understanding of the relationship between patient characteristics, positive clinical o...

Descripción completa

Detalles Bibliográficos
Autores: Puig L, Costanzo A, de Jong EMGJ, Torres T, Warren RB, Wapenaar R, Wegner S, Gorecki P, Gramiccia T, Jazra M, Buyze J, Conrad C
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p17068
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17068
https://ddd.uab.cat/record/291419
Access Level:acceso abierto
id ES_e536bc3f227fcfcba6398be673f4d4db
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p17068
network_acronym_str ES
network_name_str España
repository_id_str
spelling Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical TrialPuig LCostanzo Ade Jong EMGJTorres TWarren RBWapenaar RWegner SGorecki PGramiccia TJazra MBuyze JConrad CBackground Treatment of moderate-to-severe plaque psoriasis with biologics, such as guselkumab, has demonstrated greater efficacy over traditional non-biologic treatments. However, given patient diversity, greater understanding of the relationship between patient characteristics, positive clinical outcomes, and long-term response to biologics is crucial for optimizing treatment choices.Materials and Methods This post-hoc analysis of the 5-year VOYAGE 1 clinical trial compares baseline characteristics of patients maintaining a Psoriasis Area and Severity Index (PASI) score of 0 at all visits for >= 156 consecutive weeks (PASI = 0 group) with those that never achieve PASI = 0 (comparator group), using descriptive statistics and a multiple logistic regression model. Guselkumab plasma trough concentrations in both response groups were assessed from Weeks 4-156.Results Of patients who started guselkumab treatment at Week 0 or at Week 16 after switching from placebo, 22.7% (112/494) maintained PASI = 0 for >= 156 consecutive weeks. Numerical differences in baseline characteristics, including age, obesity, diabetes, PASI score, disease duration, smoking status, and psoriatic arthritis comorbidity, were identified between the PASI = 0 group and comparator group. Plasma guselkumab levels were consistently higher in the PASI = 0 group. Multiple logistic regression analysis revealed absence of diabetes, lower Dermatology Life Quality Index score at baseline, and higher Week 4 guselkumab plasma concentration as significantly (p < 0.05) associated with the PASI = 0 group.Conclusion A substantial (22.7%) number of guselkumab-treated patients in the VOYAGE 1 clinical trial maintained complete skin clearance for a consecutive period of >= 156 weeks. Factors associated with this outcome may suggest clinical benefits of holistic treatment approaches.ADIS INT LTD2024info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17068https://ddd.uab.cat/record/291419AMERICAN JOURNAL OF CLINICAL DERMATOLOGYISSN: 11750561ISSNe: 11791888reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p170682026-06-14T12:41:47Z
dc.title.none.fl_str_mv Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
title Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
spellingShingle Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
Puig L
title_short Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
title_full Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
title_fullStr Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
title_full_unstemmed Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
title_sort Guselkumab-Treated Patients with Plaque Psoriasis Who Achieved Complete Skin Clearance for = 156 Consecutive Weeks: A Post-Hoc Analysis From the VOYAGE 1 Clinical Trial
dc.creator.none.fl_str_mv Puig L
Costanzo A
de Jong EMGJ
Torres T
Warren RB
Wapenaar R
Wegner S
Gorecki P
Gramiccia T
Jazra M
Buyze J
Conrad C
author Puig L
author_facet Puig L
Costanzo A
de Jong EMGJ
Torres T
Warren RB
Wapenaar R
Wegner S
Gorecki P
Gramiccia T
Jazra M
Buyze J
Conrad C
author_role author
author2 Costanzo A
de Jong EMGJ
Torres T
Warren RB
Wapenaar R
Wegner S
Gorecki P
Gramiccia T
Jazra M
Buyze J
Conrad C
author2_role author
author
author
author
author
author
author
author
author
author
author
description Background Treatment of moderate-to-severe plaque psoriasis with biologics, such as guselkumab, has demonstrated greater efficacy over traditional non-biologic treatments. However, given patient diversity, greater understanding of the relationship between patient characteristics, positive clinical outcomes, and long-term response to biologics is crucial for optimizing treatment choices.Materials and Methods This post-hoc analysis of the 5-year VOYAGE 1 clinical trial compares baseline characteristics of patients maintaining a Psoriasis Area and Severity Index (PASI) score of 0 at all visits for >= 156 consecutive weeks (PASI = 0 group) with those that never achieve PASI = 0 (comparator group), using descriptive statistics and a multiple logistic regression model. Guselkumab plasma trough concentrations in both response groups were assessed from Weeks 4-156.Results Of patients who started guselkumab treatment at Week 0 or at Week 16 after switching from placebo, 22.7% (112/494) maintained PASI = 0 for >= 156 consecutive weeks. Numerical differences in baseline characteristics, including age, obesity, diabetes, PASI score, disease duration, smoking status, and psoriatic arthritis comorbidity, were identified between the PASI = 0 group and comparator group. Plasma guselkumab levels were consistently higher in the PASI = 0 group. Multiple logistic regression analysis revealed absence of diabetes, lower Dermatology Life Quality Index score at baseline, and higher Week 4 guselkumab plasma concentration as significantly (p < 0.05) associated with the PASI = 0 group.Conclusion A substantial (22.7%) number of guselkumab-treated patients in the VOYAGE 1 clinical trial maintained complete skin clearance for a consecutive period of >= 156 weeks. Factors associated with this outcome may suggest clinical benefits of holistic treatment approaches.
publishDate 2024
dc.date.none.fl_str_mv 2024
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17068
https://ddd.uab.cat/record/291419
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=17068
https://ddd.uab.cat/record/291419
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ADIS INT LTD
publisher.none.fl_str_mv ADIS INT LTD
dc.source.none.fl_str_mv AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
ISSN: 11750561
ISSNe: 11791888
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869422659009249280
score 15,811543

Similares en LA Referencia